
Teleflex Study Shows 70.5% Reduction in CLABSI with Antimicrobial CVCs
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced findings from a new multinational study demonstrating the efficacy of its Arrowâ„¢ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated …
Teleflex Study Shows 70.5% Reduction in CLABSI with Antimicrobial CVCs Read More